Cargando…

Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)

This clinical trial (ChiCTR1800019185) is designed to be an open‐label, prospective, single‐center, single arm exploratory research study. The study will recruit non‐small cell lung cancer patients (NSCLC) with slow progression after first‐line treatment with EGFR‐TKI drugs. Slow progression will be...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xin, Liu, Minghui, Zhang, Hongbing, Liu, Hongyu, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049491/
https://www.ncbi.nlm.nih.gov/pubmed/31918452
http://dx.doi.org/10.1111/1759-7714.13303
_version_ 1783502452056653824
author Li, Xin
Liu, Minghui
Zhang, Hongbing
Liu, Hongyu
Chen, Jun
author_facet Li, Xin
Liu, Minghui
Zhang, Hongbing
Liu, Hongyu
Chen, Jun
author_sort Li, Xin
collection PubMed
description This clinical trial (ChiCTR1800019185) is designed to be an open‐label, prospective, single‐center, single arm exploratory research study. The study will recruit non‐small cell lung cancer patients (NSCLC) with slow progression after first‐line treatment with EGFR‐TKI drugs. Slow progression will be confirmed by the presence of serum carcinoembryonic antigen or imaging evaluation. The primary aim is to assess progression‐free survival after EGFR‐TKIs treatment combined with apatinib 250 mg once daily. The secondary objectives are to evaluate objective efficacy, disease control rates, quality of life, overall survival, and safety. From September 2018 to September 2020, under specific entry and discharge standards, we plan to enroll 38 eligible patients until the end of the study. We hope that our study will help to explore a new way of combining the small molecular inhibitors of antiangiogenesis with EGFR‐TKIs to overcome acquired drug resistance.
format Online
Article
Text
id pubmed-7049491
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-70494912020-03-05 Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185) Li, Xin Liu, Minghui Zhang, Hongbing Liu, Hongyu Chen, Jun Thorac Cancer Study Protocol This clinical trial (ChiCTR1800019185) is designed to be an open‐label, prospective, single‐center, single arm exploratory research study. The study will recruit non‐small cell lung cancer patients (NSCLC) with slow progression after first‐line treatment with EGFR‐TKI drugs. Slow progression will be confirmed by the presence of serum carcinoembryonic antigen or imaging evaluation. The primary aim is to assess progression‐free survival after EGFR‐TKIs treatment combined with apatinib 250 mg once daily. The secondary objectives are to evaluate objective efficacy, disease control rates, quality of life, overall survival, and safety. From September 2018 to September 2020, under specific entry and discharge standards, we plan to enroll 38 eligible patients until the end of the study. We hope that our study will help to explore a new way of combining the small molecular inhibitors of antiangiogenesis with EGFR‐TKIs to overcome acquired drug resistance. John Wiley & Sons Australia, Ltd 2020-01-09 2020-03 /pmc/articles/PMC7049491/ /pubmed/31918452 http://dx.doi.org/10.1111/1759-7714.13303 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Li, Xin
Liu, Minghui
Zhang, Hongbing
Liu, Hongyu
Chen, Jun
Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
title Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
title_full Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
title_fullStr Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
title_full_unstemmed Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
title_short Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
title_sort clinical study of apatinib combined with egfr‐tki in the treatment of chronic progression after egfr‐tki treatment in non‐small cell lung cancer (chictr1800019185)
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049491/
https://www.ncbi.nlm.nih.gov/pubmed/31918452
http://dx.doi.org/10.1111/1759-7714.13303
work_keys_str_mv AT lixin clinicalstudyofapatinibcombinedwithegfrtkiinthetreatmentofchronicprogressionafteregfrtkitreatmentinnonsmallcelllungcancerchictr1800019185
AT liuminghui clinicalstudyofapatinibcombinedwithegfrtkiinthetreatmentofchronicprogressionafteregfrtkitreatmentinnonsmallcelllungcancerchictr1800019185
AT zhanghongbing clinicalstudyofapatinibcombinedwithegfrtkiinthetreatmentofchronicprogressionafteregfrtkitreatmentinnonsmallcelllungcancerchictr1800019185
AT liuhongyu clinicalstudyofapatinibcombinedwithegfrtkiinthetreatmentofchronicprogressionafteregfrtkitreatmentinnonsmallcelllungcancerchictr1800019185
AT chenjun clinicalstudyofapatinibcombinedwithegfrtkiinthetreatmentofchronicprogressionafteregfrtkitreatmentinnonsmallcelllungcancerchictr1800019185